Results 51 to 60 of about 35,110 (216)

Mechanisms of Cetuximab Resistance and How to Overcome It [PDF]

, 2021
AbstractDeregulated or increased signalling of the epidermal growth factor receptor (EGFR) plays an integral role in the development of various cancer types, including head and neck squamous cell carcinoma (HNSCC), making it a compelling drug target. However, after initially promising results of EGFR-targeted therapies, such as the monoclonal antibody ...
Ines De Pauw, Carolien Boeckx, An Wouters   +2 more
openaire   +1 more source

Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression

Molecular Cancer, 2022
Background Epithelial-to-mesenchymal transition (EMT) is a process linked to metastasis and drug resistance with non-coding RNAs (ncRNAs) playing pivotal roles. We previously showed that miR-100 and miR-125b, embedded within the third intron of the ncRNA
Hao Liu, Danxiu Li, Lina Sun, Hongqiang Qin, Ahui Fan, Lingnan Meng, Ramona Graves-Deal, Sarah E. Glass, Jeffrey L. Franklin, Qi Liu, Jing Wang, Timothy J. Yeatman, Hao Guo, Hong Zong, Shuilin Jin, Zhiyu Chen, Ting Deng, Ying Fang, Cunxi Li, John Karijolich, James G. Patton, Xin Wang, Yongzhan Nie, Daiming Fan, Robert J. Coffey, Xiaodi Zhao, Yuanyuan Lu   +26 more
doaj   +1 more source

BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. [PDF]

Cancer Res, 2018
Abstract Cetuximab, the FDA-approved anti-EGFR antibody for head and neck squamous cell carcinoma (HNSCC), has displayed limited efficacy due to the emergence of intrinsic and acquired resistance. We and others have demonstrated that cetuximab resistance in HNSCC is driven by alternative receptor tyrosine kinases (RTK), including HER3,
Leonard B, Brand TM, O'Keefe RA, Lee ED, Zeng Y, Kemmer JD, Li H, Grandis JR, Bhola NE.   +8 more
europepmc   +6 more sources

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]

, 2010
The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp, Harreus, Ulrich, Reiter, Maximilian, Schwenk-Zieger, Sabina   +3 more
core   +1 more source

Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer [PDF]

, 2019
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of
Belardinilli, Francesca, Cortesi, Enrico, Gazzaniga, Paola, Gelibter, ALAIN JONATHAN, Giannini, Giuseppe, Gradilone, Angela, Loreni, Flavia, Mahdavia, Yasaman, Nicolazzo, Chiara, Raimondi, Cristina   +9 more
core   +1 more source

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer

Cell Death and Disease, 2021
Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC.
Jiawen Yang, Jiajie Mo, Juji Dai, Chenqiao Ye, Wei Cen, Xuzhi Zheng, Lei Jiang, Lechi Ye   +7 more
doaj   +1 more source

MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3. [PDF]

Cancer Biol Ther
Despite advances in targeted therapies, primary and acquired resistance make the treatment of colorectal cancer (CRC) a pressing issue to be resolved. According to reports, the development of CRC is linked to miRNA dysregulation. Multiple studies have demonstrated that miR-135b-5p has an aberrant expression level between CRC tissues and adjacent ...
Peng C, Li X, Yao Y, Nie Y, Fan L, Zhu C.   +5 more
europepmc   +4 more sources

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. [PDF]

, 2014
BackgroundAfatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor (EGFR)-mutated lung cancer.
Blackman, A, Clement, PM, Cohen, EEW, Cupissol, D, Degardin, M, Del Campo, JM, Ehrnrooth, E, Fayette, J, Hitt, R, Seiwert, TY, Zhang, W   +10 more
core   +2 more sources

Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance

Nature Communications, 2022
Acquired resistance to cetuximab can be mediated by generation of mutations in the EGFR ectodomain. Here the authors report a structure-guided and phage-assisted evolution approach for cetuximab evolution to reverse resistance without altering the ...
Xinlei Zhuang, Zhe Wang, Jiansheng Fan, Xuefei Bai, Yingchun Xu, James J. Chou, Tingjun Hou, Shuqing Chen, Liqiang Pan   +8 more
doaj   +1 more source

Long noncoding RNA and mRNA profiling in cetuximab‐resistant colorectal cancer cells by RNA sequencing analysis

Cancer Medicine, 2019
To gain an insight into the molecular mechanisms of cetuximab resistance in colorectal cancer, we generated a cetuximab‐resistant cell line (H508/CR) and performed RNA sequencing to identify the differential expression patterns of noncoding RNAs (ncRNAs)
Changwen Jing, Rong Ma, Haixia Cao, Zhuo Wang, Siwen Liu, Dan Chen, Yang Wu, Junying Zhang, Jianzhong Wu   +8 more
doaj   +1 more source